Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06132503 · ClinicalTrials.gov registry record · Phase 1

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Relapsed or Refractory Lymphomas, sponsored by Lantern Pharma.

Recruiting
Registry status
Phase 1
Development phase
110
Enrollment target
4
Study locations

NCT06132503 is a Phase 1 study of Advanced Solid Tumor and Relapsed or Refractory Lymphomas that is actively recruiting participants, run by Lantern Pharma. The registered enrollment target is 110 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (43% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06132503, a Phase 1 study of Advanced Solid Tumor and Relapsed or Refractory Lymphomas, is actively recruiting participants, sponsored by Lantern Pharma.

RECRUITING
Registry status
Phase 1
Development phase
110 participants
Enrollment target
4
Study locations

Study Summary

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are to characterize the pharmacokinetics (PK) of LP-284 and to assess clinical activity of LP-284.

Conditions Studied

Advanced Solid Tumor Relapsed or Refractory Lymphomas

Interventions

  • DRUG LP-284

Study Locations (4)

California

  • Cancer and Blood Specialists Clinic - Los Alamitos

Florida

  • Florida Cancer Specialists - Lake Mary

Tennessee

  • SCRI Oncology Partners - Nashville

Utah

  • START Mountain Region - West Valley City

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2023-01-03
Est. Completion 2028-11-30
Phase Phase 1

Sponsor

Lantern Pharma

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06132503

The ClinicalTrials.gov registry entry for NCT06132503 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (43% lower). The listed sponsor is Lantern Pharma, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which LP-284 is the first listed.

NCT06132503 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06132503 about?

NCT06132503 is a clinical study titled "Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors". The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are to...

What is the current status of trial NCT06132503?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2023-01-03. Estimated completion is 2028-11-30.

What conditions does trial NCT06132503 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Relapsed or Refractory Lymphomas.

What interventions are being tested in trial NCT06132503?

The interventions under investigation include: LP-284 (DRUG).

Who is sponsoring clinical trial NCT06132503?

This trial is sponsored by Lantern Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06132503 being conducted?

This trial has 4 study locations across California, Florida, Tennessee, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Relapsed or Refractory Lymphomas

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.